Is LABD a Good Investment? The Case For and Against (2026)

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a geared inverse exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 300% of the inverse (-3x) of the daily performance of the S&P Biotechnology Select Industry Index. The fund uses swaps, futures, and short positions rather than holding a portfolio of stocks, so its disclosed holdings are derivative and cash instruments rather than individual companies. The S&P Biotechnology Select Industry Index is an equal-weighted portfolio of US biotechnology firms, a sector already known for sharp, news-driven swings around clinical trials, FDA decisions, and earnings. Applying -3x leverage to that base magnifies both gains and losses. Critically, LABD targets its -3x exposure on a single-day basis and rebalances daily. Over any holding period longer than one day, the compounding of daily returns means LABD's performance can diverge substantially from -3x the index's cumulative return, and in choppy or sideways markets this compounding works against holders, eroding value even if biotech is roughly flat. LABD carries a gross expense ratio around 1.07% (net near 0.95%), well above plain index funds, which adds a further long-term drag. It is designed for sophisticated traders seeking to profit from or hedge against short-term declines in biotech, with positions actively monitored and typically held for days, not months. Its bull counterpart is LABU (Direxion Daily S&P Biotech Bull 3X Shares), which seeks +3x the same index.

Largest holdings (approximate as of early 2026; verify on Direxion's fund page):

LABD is Direxion's -3x inverse leveraged biotech ETF: it seeks 300% of the opposite of the daily move in the S&P Biotechnology Select Industry index, so it gains when biotech falls. It is a short-term hedging and trading instrument only. Daily resetting plus already-volatile biotech means it suffers compounding decay and tends to lose value if held longer than a day or two, regardless of the index's direction.

In its favour: it gives you -3x daily S&P Biotech Select Industry exposure in one ticker at a 1.07% (gross; about 0.95% net of acquired fund fees) expense ratio, which is simple to hold and cheap to own.

• Cost vs alternatives: 1.07% (gross; about 0.95% net of acquired fund fees) is the fee; compare it to funds tracking a similar index.
• Concentration: check how much of LABD sits in its largest holdings ().
• Overlap: if you already own a broad-market fund, you may already hold much of this.
• Tracking scope: LABD only gives you -3x daily S&P Biotech Select Industry; it will not capture what sits outside that index.

“Diversified” is the word every index fund uses and it hides a wide range. The number that actually matters is how much of the fund sits in its largest positions, because that is the part that drives the return. Published weights for LABD are not detailed enough here to total reliably, so check the largest positions on Direxion's fund page before assuming the spread is even.

Where a fund does not make its concentration easy to see, treat that as a reason to look rather than a reason to assume.

This is also the number that decides whether LABD adds diversification to your portfolio rather than to a portfolio in the abstract. A fund can be well spread on its own and still concentrate you further, if its largest holdings are names you already own directly or through another fund. That is a question about your account rather than about LABD, and it is the one worth answering before you buy.

A fund is defined as much by what it leaves out as by what it holds, and the exclusions are rarely on the marketing page. LABD tracks -3x daily S&P Biotech Select Industry, so anything outside that index is simply absent from your portfolio no matter how much of the fund you own.

In practice that means checking three gaps. Whether the geography you want is covered, since a US index holds no international companies and a developed-markets index holds no emerging ones. Whether the size band you want is covered, because a large-cap index excludes the smaller companies some investors specifically want exposure to. And whether the asset class you want is covered at all, since an equity fund holds no bonds and gives you nothing to rebalance against in a drawdown.

None of these are faults. They are the fund doing exactly what it says. The mistake is assuming that owning a diversified fund means being diversified, when it means being diversified within one index.

Being specific about this is more useful than another paragraph on why it might be right.

• You already own most of it. If a broad-market fund you hold already contains at meaningful weight, adding LABD mostly increases your exposure to the same companies while adding a second fee. That is the single most common way people accidentally concentrate.
• You want the exposure for a short horizon. An index fund is a way to own an asset class over years. Over months it is simply the index, with all of the index's volatility and none of the compounding that makes holding it worthwhile.
• You need income you can rely on. Distributions from an equity index fund vary with what the underlying companies pay, so they are not a schedule you can plan around the way a bond ladder is.
• A cheaper fund tracks the same thing. Where two funds follow a similar index, the difference in expense ratio is one of the few advantages available to you without taking extra risk. Compare before assuming 1.07% (gross; about 0.95% net of acquired fund fees) is competitive.

The useful question is rarely “will LABD go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how LABD would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.

The bottom line: LABD is a low-cost core building block for -3x daily S&P Biotech Select Industry exposure, not a tactical bet on a single name. If you want -3x daily S&P Biotech Select Industry exposure and the 1.07% (gross; about 0.95% net of acquired fund fees) fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.

• What is LABD? (holdings, cost, performance, and the themes it covers)
• LABD dividend: yield and schedule